This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D76.1 | Synonyms: Mononuclear phagocyte system histiocytosis, MPS histiocytosis
The concept of the mononuclear phagocyte system (MPS) was proposed in 1969 by van Furth and colleagues to replace the earlier concept of the reticuloendothelial system, and it encompasses a series of cell lineages derived from bone marrow monocyte precursors, including blood monocytes, tissue macrophages, and dendritic cells. The group of diseases arising when these cells proliferate or accumulate abnormally came to be collectively called MPS histiocytosis.
The classification of histiocytic disorders has developed continuously. In 1987, the Writing Group of the Histiocyte Society classified histiocytic disorders as dendritic cell-related (class I), macrophage-related (class II, including HLH), and malignant histiocytic disorders (class III). In 2016, Emile and colleagues proposed a new five-group classification system (groups L, C, M, R, H) reflecting advances in research on hematologic malignancies and immunology.
In Korea, pathological awareness of histiocytic disorders has increased since the 1990s, and with the introduction of molecular genetics-based diagnosis in the 2000s, classification of individual diseases within mononuclear phagocyte histiocytosis is being applied in clinical practice.
Histiocytosis of mononuclear phagocytes is mostly of reactive origin, with monocytes-macrophages abnormally activated and proliferating in response to various stimuli. The main reactive causes include infections (bacterial, viral, fungal, parasitic), autoimmune diseases (SLE, rheumatoid arthritis, sarcoidosis), metabolic abnormalities (lipid storage diseases), and foreign body reactions.
Primary mononuclear phagocyte histiocytosis is caused by genetic abnormalities of MPS cells themselves or by defects in regulatory mechanisms. Typically, pathological histiocytosis of macrophages appears in familial HLH (PRF1, UNC13D, STX11, STXBP2 mutations) and lipid storage diseases (Gaucher disease, Niemann-Pick disease, etc.).
In some cases, mononuclear phagocyte histiocytosis undergoes malignant transformation and progresses to malignant histiocytosis or dendritic cell sarcoma.
The development and function of mononuclear phagocytes are regulated by CSF1R (the M-CSF receptor), transcription factors such as IRF8 and PU.1, and MAPK pathway genes such as MAP2K1, BRAF. The BRAF V600E somatic mutation is found at a frequency of 50~60% in Langerhans cell histiocytosis (LCH) and some mononuclear phagocyte histiocytoses.
| Disease | Gene | Mode of inheritance | Defective enzyme |
|---|---|---|---|
| Gaucher disease | GBA | Autosomal recessive | Glucocerebrosidase |
| Niemann-Pick disease types A/B | SMPD1 | Autosomal recessive | Acid sphingomyelinase |
| Niemann-Pick disease type C | NPC1/NPC2 | Autosomal recessive | Cholesterol transport |
| Tay-Sachs disease | HEXA | Autosomal recessive | Hexosaminidase A |
Most reactive mononuclear phagocyte histiocytoses have no genetic predisposition, but in malignant forms, somatic mutations of BRAF, MAP2K1, CSF1R, and others are found.
Because histiocytosis of mononuclear phagocytes includes a heterogeneous group of diseases, it is difficult to give a single prevalence figure. Reactive mononuclear phagocytosis arises secondarily to a variety of diseases and is therefore observed relatively commonly in clinical practice. Primary and rare MPS histiocytoses (including HLH) are extremely rare.
The age distribution varies by underlying disease. Childhood onset is common in hereditary lipid storage diseases, and reactive MPS histiocytosis occurs at all ages.
In Korea, lipid storage diseases (particularly Gaucher disease) are rarely diagnosed, and in such cases they are accompanied by findings of MPS histiocytosis. Reactive MPS histiocytosis occurs relatively commonly with underlying causes such as tuberculosis, EBV infection, and autoimmune diseases.
Normally, monocytes-macrophages perform key roles such as healing of damaged tissue, pathogen clearance, and immune regulation. Under pathological conditions, when these cells are persistently activated, abnormal accumulation in tissues (histiocytosis) occurs. In reactive MPS histiocytosis, persistent stimulation by infectious agents or autoantigens induces macrophage activation and proliferation.
In lipid storage diseases such as Gaucher disease, deficiency of a specific lysosomal enzyme causes substrates (glucocerebroside, etc.) to accumulate in macrophages, forming foam cells or Gaucher cells. These cells deposit in the spleen, liver, bone marrow, and elsewhere, causing organ failure.
In the presence of MAPK pathway somatic mutations such as BRAF V600E, a persistent proliferation signal arises in MPS cells, leading to clonal histiocytosis. This is the core pathogenetic mechanism of Langerhans cell histiocytosis and some malignant histiocytic disorders.
Systemic symptoms such as fever, weight loss, and night sweats may occur. These are caused by cytokines (TNF-α, IL-6, IL-1β) secreted by activated macrophages.
Abdominal discomfort and early satiety due to splenomegaly. Right upper quadrant discomfort and jaundice due to hepatomegaly. With bone marrow involvement, symptoms due to anemia and thrombocytopenia. With lung involvement, dyspnea and cough. With central nervous system involvement, headache, altered consciousness, and neurological symptoms may occur.
Skin involvement such as skin nodules, papules, and xanthomas may occur in some subtypes of MPS histiocytosis.
Symptoms related to the underlying disease (infection, autoimmunity, malignancy) are also present.
Splenomegaly (often marked massive splenomegaly), hepatomegaly, and lymphadenopathy are the main findings. With bone marrow involvement, pallor, petechiae, and ecchymoses are observed. Some subtypes show findings of skin involvement (nodules, xanthomatous lesions).
Tissue biopsy is characterized by extensive infiltration of cells of the monocyte-macrophage lineage. Foam cells: in lipid storage diseases, lipid accumulation within lysosomes gives the cytoplasm a foamy appearance. Hemophagocytosis: in HLH, macrophages are seen phagocytosing red blood cells, white blood cells, and platelets. On immunohistochemistry, CD68 and CD163 positivity (macrophage markers) is characteristic.
Anemia, thrombocytopenia, leukopenia or leukocytosis. Elevated serum ferritin, elevated LDH, elevated CRP. Liver function abnormalities (elevated AST/ALT, elevated bilirubin). In lipid storage diseases, reduced activity of the specific enzyme (e.g., reduced glucocerebrosidase activity in Gaucher disease).
MPS histiocytosis is suspected and further tests are performed in patients with unexplained splenomegaly, hepatomegaly, and pancytopenia. Tests to differentiate underlying diseases (infection, autoimmunity, malignancy) are performed in parallel.
When a lipid storage disease is suspected, the relevant enzyme activity test (dried blood spot testing or leukocyte enzyme activity measurement) is used as a screening test. Gaucher disease: measurement of glucocerebrosidase activity. Niemann-Pick disease: sphingomyelinase or NPC1/2 variant analysis.
Some lipid storage diseases (Gaucher disease, Niemann-Pick disease, etc.) are included in newborn screening panels, and in Korea, too, some lipid storage diseases can be detected through the expanded newborn screening program.
Infiltration by mononuclear phagocyte lineage cells and hemophagocytosis are confirmed on spleen, lymph node, bone marrow, and liver biopsies. Cell types are identified by immunohistochemical staining (CD68, CD163, CD14, S100, CD1a, etc.) to differentiate HLH, Langerhans cell histiocytosis, malignant histiocytosis, and others.
Analysis of HLH-related genes (PRF1, UNC13D, STX11, STXBP2) using NGS panels. Analysis of causative genes of lipid storage diseases (GBA, SMPD1, NPC1/2, etc.). Testing for somatic mutations such as BRAF V600E (when malignant transformation is suspected).
The primary treatment of reactive MPS histiocytosis is treatment of the underlying disease. Elimination of infectious causes (antibiotics, antivirals, antifungals), treatment of autoimmunity (immunosuppressants), and treatment of malignancy (chemotherapy) are central.
Gaucher disease: enzyme replacement therapy (imiglucerase, velaglucerase, etc.) or substrate reduction therapy (miglustat, eliglustat). Niemann-Pick disease type C: miglustat to delay progression of neurological symptoms. Others: specific treatment for each lipid storage disease is given.
In BRAF V600E-positive clonal histiocytosis, the use of vemurafenib (a BRAF inhibitor) and MEK inhibitors (cobimetinib, etc.) has been reported. JAK inhibitors (ruxolitinib) are under clinical study in reactive MPS histiocytosis and MAS.
Reactive MPS histiocytosis has a relatively favorable prognosis because the histiocytosis resolves once the underlying cause is successfully treated. Primary HLH is fatal if untreated, and the 5-year survival rate after hematopoietic stem cell transplantation is about 60~70%. In lipid storage diseases (particularly Gaucher disease), symptoms improve greatly with enzyme replacement therapy, but the prognosis is poor when there are neurological complications. Malignant histiocytosis has a very poor prognosis.
Long-term complications such as blood cell sequestration due to splenomegaly, cirrhosis, and pulmonary fibrosis limit the prognosis in patients with a chronic course.
Genetic counseling and carrier screening are performed in families of patients with hereditary MPS histiocytosis, such as lipid storage diseases and primary HLH. Prenatal genetic testing (CVS or amniocentesis) can diagnose an affected fetus early.
Infections, the main cause of reactive MPS histiocytosis, are prevented and, when they occur, treated early and aggressively. Prophylaxis against opportunistic infections is given to immunosuppressed patients.
In patients with hereditary lipid storage diseases, spleen size, the extent of bone marrow involvement, and organ function are monitored regularly to detect complications early and adjust treatment.